AZD9550 vs DA-1726
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
AZD9550
Developed by AstraZeneca
NCT06862791 · Phase 2 · completed
The study uses randomization, quadruple blinding, multiple placebo-controlled treatment groups, and includes 377 participants. Its primary endpoints are clinical weight-loss measures, but the results and whether the primary comparisons were met are not yet available, so the evidence cannot be rated as strong.
Next expected readout: January 2027 · NCT06151964 (registry estimate)
No aligned efficacy figure on record for this race.
DA-1726
Developed by MetaVia under a licence from Dong-A ST
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Obesity
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | AZD9550 | DA-1726 |
|---|---|---|
| Body weight, % change | —Not reported | —Not reported |
| Weight loss of 5% or more | —Not reported | —Not reported |
| Weight loss of 10% or more | —Not reported | —Not reported |
| Waist circumference, change (cm) | —Not reported | —Not reported |
Body weight, % change
- AZD9550
- —Not reported
- DA-1726
- —Not reported
Weight loss of 5% or more
- AZD9550
- —Not reported
- DA-1726
- —Not reported
Weight loss of 10% or more
- AZD9550
- —Not reported
- DA-1726
- —Not reported
Waist circumference, change (cm)
- AZD9550
- —Not reported
- DA-1726
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
AZD9550: no structured comparison results are available for Obesity.
DA-1726: no structured comparison results are available for Obesity.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD9550's landscape · DA-1726's landscape